Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) announced that its CEO, Mike Sherman, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on March 7, 2023, at 2:10 p.m. ET. An audio webcast of the discussion will be available on the company's Investor Relations section of their website, where it will remain archived for approximately 90 days.

Chimerix is focused on developing medicines to improve the lives of patients facing serious diseases, with its most advanced program, ONC201, targeting H3 K27M-mutant glioma.

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43^rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET.

An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACTS:

Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Nick Lamplough / Dan Moore / Tanner Kaufman
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

FAQ

When is Mike Sherman's panel participation at the Cowen Healthcare Conference?

Mike Sherman will participate in the panel on March 7, 2023, at 2:10 p.m. ET.

Where can I listen to the audio webcast of the panel discussion?

The audio webcast will be available on Chimerix's Investor Relations section of their website.

What is the primary focus of Chimerix's drug development?

Chimerix focuses on developing medicines to improve the lives of patients with deadly diseases, particularly ONC201 for H3 K27M-mutant glioma.

How long will the webcast be archived after the conference?

The webcast will be archived for approximately 90 days.

What is Chimerix's stock symbol?

Chimerix's stock symbol is CMRX.